Skip to content

Academic-Community EPINET (AC-EPINET)

Academic-Community EPINET (AC-EPINET): Mitigating Barriers to Care PILOT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04497857
Acronym
AC-EPINET
Enrollment
74
Registered
2020-08-04
Start date
2022-03-16
Completion date
2025-07-29
Last updated
2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Schizoaffective Disorder, Schizophrenia, Schizophreniform Disorders

Keywords

psychosis

Brief summary

The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.

Detailed description

160 subjects will be randomized into a 12 month study, to one of two treatment arms. The investigators will assess four important elements of engagement to determine which are most sensitive to TH treatment and mediates effects on hospitalization rates. The investigators will assess acceptability and satisfaction of CSC-TH compared to CSC-SD, and deliver a training manual for implementing TH in CSC clinics and for use in future research. Although this study has exploratory aims consistent with pilot projects, The investigators have incorporated methodological rigor where possible (randomization, powering for hospitalization rate) in order to achieve the most robust data to assess the main study questions and inform future trials.

Interventions

CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders

Sponsors

University of Michigan
CollaboratorOTHER
Ohio State University
CollaboratorOTHER
Vanderbilt University
CollaboratorOTHER
Tulane University
CollaboratorOTHER
University of Rochester
CollaboratorOTHER
Yale University
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

1. Between 16 and 35 years of age 2. Able to give informed consent 3. Willing and able to adhere to the study schedule 4. New intakes enrolled in one of the six clinical programs 5. Non-affective (schizophrenia, schizoaffective, schizophreniform) and affective (major depression with psychotic features, bipolar disorder with psychotic features) psychotic disorders with onsets within 5 years of enrollment.

Exclusion criteria

1\. Known IQ \< 70 based on participant report

Design outcomes

Primary

MeasureTime frameDescription
Annualized hospitalization rates12 monthsTo determine if CSC-TH, as compared to CSC-SD, is associated with superior clinical outcomes by counting the number of hospitalizations in a year

Secondary

MeasureTime frameDescription
Number of participants hospitalized12 monthsCount of the number of participants hospitalized (adjusted for time in treatment)
Time (days) to first hospitalization12 monthsCount of the time in days to first hospitalization
Symptom outcomes assessed by the Modified Colorado Symptom Index (MCSI)12 monthsThe modified Colorado Symptom Index (MCSI) is a 14-item, self-report scale designed to assess frequency of positive mood and cognitive symptoms in psychosis. Items are rated on a 5-point Likert-style scale (Not at all, Once during the month, Several times during the month, Several times a week, at least every day). Each item is scored on a 0-4 scale (not at all = 0; at least every day = 4) and added together to give a score between 0 and 56, with higher scores indicating greater emotional distress.
Symptom outcomes assessed by the COMPASS-1012 monthsThe COMPASS10 consists of 10 items selected from the COMPASS scale developed for the RAISE ETP study. The COMPASS-10 is a clinician-rated assessment of symptom severity in psychosis. There are 10 items measuring anxiety, asociality, avolition, depression, disorganization, hallucinations, hostility, suicidal ideation or behavior, suspiciousness and unusual thought content. The items are rated on a Likert scale from 0 to 6 (0 = not present, 1 =very mild, 2 = mild, 3 = moderate 4= moderately severe, 5 = severe, 6= very severe), with higher scores indicating increased severity of symptoms. For each item, assessors provide ratings of symptom severity after sufficient information is obtained through probe questions.
Functioning outcomes assessed by the MIRECC-GAF12 monthsThe MIRECC GAF ( Mental Illness Research, Education, and Clinical Center Global Assessment of Functioning) is a three scale assessment of symptom severity, occupational/school functioning, and social functioning. It is scored from 0-100, with a lower score representing worse symptoms/functioning and higher scores representing better functioning. This assessment has been found to have high levels of reliability, concurrent, and predictive validity. It is completed by a trained rater and is expected to take 5 minutes to complete, as the information needed to score the participants will be gathered in various aspects of the assessment process.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026